517 related articles for article (PubMed ID: 14567392)
1. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
Food and Drug Administration, HHS
Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
[TBL] [Abstract][Full Text] [Related]
2. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Jan; 65(4):1000-50. PubMed ID: 11010621
[TBL] [Abstract][Full Text] [Related]
3. Child-resistant packaging for certain over-the-counter drug products. Final rule.
Consumer Product Safety Commission
Fed Regist; 2001 Aug; 66(149):40111-6. PubMed ID: 11732555
[TBL] [Abstract][Full Text] [Related]
4. Unit-dose packaging of iron supplements and reduction of iron poisoning in young children.
Tenenbein M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):557-60. PubMed ID: 15939855
[TBL] [Abstract][Full Text] [Related]
5. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
6. Tamper-evident packaging requirements for over-the-counter human drug products--FDA. Final rule.
Fed Regist; 1998 Nov; 63(213):59463-71. PubMed ID: 10187120
[TBL] [Abstract][Full Text] [Related]
7. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2012 Mar; 77(54):16158-63. PubMed ID: 22479732
[TBL] [Abstract][Full Text] [Related]
8. Drug labeling; orally ingested over-the-counter drug products containing calcium, magnesium, and potassium. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Mar; 69(57):13725-35. PubMed ID: 15040351
[TBL] [Abstract][Full Text] [Related]
9. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
[TBL] [Abstract][Full Text] [Related]
10. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(28):6787-854. PubMed ID: 14968803
[TBL] [Abstract][Full Text] [Related]
11. FDA regulation of dietary supplements and requirements regarding adverse event reporting.
Frankos VH; Street DA; O'Neill RK
Clin Pharmacol Ther; 2010 Feb; 87(2):239-44. PubMed ID: 20032973
[TBL] [Abstract][Full Text] [Related]
12. Proposed rule: current good manufacturing practice in manufacturing, packing, or holding dietary ingredients and dietary supplements.
Melethil S
Life Sci; 2006 Mar; 78(18):2049-53. PubMed ID: 16516243
[TBL] [Abstract][Full Text] [Related]
13. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Jun; 72(121):34751-958. PubMed ID: 17674484
[TBL] [Abstract][Full Text] [Related]
14. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body; partial stay of compliance. Food and Drug Administration, HHS. Final rule; partial stay of compliance.
Fed Regist; 2000 Sep; 65(190):58346-50. PubMed ID: 11503646
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
[TBL] [Abstract][Full Text] [Related]
16. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
[TBL] [Abstract][Full Text] [Related]
17. Labeling for oral and rectal over-the-counter drug products containing aspirin and nonaspirin salicylates; Reye's Syndrome warning. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Apr; 68(74):18861-9. PubMed ID: 12701599
[TBL] [Abstract][Full Text] [Related]
18. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
[TBL] [Abstract][Full Text] [Related]
19. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
[TBL] [Abstract][Full Text] [Related]
20. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final rule for over-the-counter antitussive drug products; technical amendment. Final rule, technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2007 Nov; 72(230):67639-40. PubMed ID: 18064767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
